Perspective Therapeutics (CATX) Stock Overview
A radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CATX Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Perspective Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.17 |
| 52 Week High | US$6.16 |
| 52 Week Low | US$1.60 |
| Beta | 1.8 |
| 1 Month Change | -22.78% |
| 3 Month Change | 51.64% |
| 1 Year Change | 112.76% |
| 3 Year Change | -35.60% |
| 5 Year Change | -63.10% |
| Change since IPO | -58.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| CATX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.8% | 3.2% | -0.6% |
| 1Y | 112.8% | 31.7% | 16.0% |
Return vs Industry: CATX exceeded the US Biotechs industry which returned 25.8% over the past year.
Return vs Market: CATX exceeded the US Market which returned 14% over the past year.
Price Volatility
| CATX volatility | |
|---|---|
| CATX Average Weekly Movement | 24.0% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: CATX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CATX's weekly volatility has increased from 17% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 165 | Thijs Spoor | www.perspectivetherapeutics.com |
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer.
Perspective Therapeutics, Inc. Fundamentals Summary
| CATX fundamental statistics | |
|---|---|
| Market cap | US$436.37m |
| Earnings (TTM) | -US$103.63m |
| Revenue (TTM) | US$884.00k |
Is CATX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CATX income statement (TTM) | |
|---|---|
| Revenue | US$884.00k |
| Cost of Revenue | US$84.22m |
| Gross Profit | -US$83.33m |
| Other Expenses | US$20.30m |
| Earnings | -US$103.63m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | -9,426.58% |
| Net Profit Margin | -11,723.42% |
| Debt/Equity Ratio | 0.8% |
How did CATX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/31 12:46 |
| End of Day Share Price | 2026/03/31 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Perspective Therapeutics, Inc. is covered by 22 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Alec Stranahan | BofA Global Research |
| Yuan Zhi | B. Riley Securities, Inc. |